24 research outputs found
ΠΠΠΠΠΠΠΠΠ‘Π’Π ΠΠ ΠΠΠΠΠΠΠΠ― ΠΠΠ’ΠΠΠΠΠΠ‘Π’ΠΠ ΠΠΠΠΠΠ’Π ΠΠΠΠΠΠ«Π₯ Π ΠΠ¦ΠΠΠ’ΠΠ ΠΠ ΠΠ Π Π ΠΠΠΠ«Π₯ Π€ΠΠΠΠ’ΠΠΠΠ₯ ΠΠ ΠΠΠ₯ΠΠΠΠ¬ΠΠΠ ΠΠ‘Π’ΠΠ«
Cysteinyl leukotrienes which are products of lipoxygenase pathway of arachidonic acid metabolism play an important role in all phenotypes of bronchial asthma (BA). They are involved in immune and non-immune stimulation of different cells and inflammatory mechanisms in BA. Leukotrienes cause bronchoconstriction, increase vascular permeability and bronchial mucosa oedema, stimulate mucus secretion. Knowledge ofleukotriene as inflammation mediators has allowed development leukotriene receptor antagonists and their implementation in clinical practice. Antiinflammatory properties of leukotriene receptor antagonists facilitate achievement asthma control while using both as monotherapy in mild asthma and in combinations with other antiasthmatic drugs in more severe disease. Currently, ongoing research of asthma phenotypes could definecertain phenotypes with more important role of leukotrienes.Π¦ΠΈΡΡΠ΅ΠΈΠ½ΠΈΠ»ΠΎΠ²ΡΠ΅ Π»Π΅ΠΉΠΊΠΎΡΡΠΈΠ΅Π½Ρ (Lt) β ΠΏΡΠΎΠ΄ΡΠΊΡ Π»ΠΈΠΏΠΎΠΊΡΠΈΠ³Π΅Π½Π°Π·Π½ΠΎΠ³ΠΎ ΠΌΠ΅ΡΠ°Π±ΠΎΠ»ΠΈΠ·ΠΌΠ° Π°ΡΠ°Ρ
ΠΈΠ΄ΠΎΠ½ΠΎΠ²ΠΎΠΉ ΠΊΠΈΡΠ»ΠΎΡΡ β ΠΈΠ³ΡΠ°ΡΡ Π²Π°ΠΆΠ½ΡΡ ΡΠΎΠ»Ρ ΠΏΡΠΈ Π²ΡΠ΅Ρ
ΡΠ΅Π½ΠΎΡΠΈΠΏΠ°Ρ
Π±ΡΠΎΠ½Ρ
ΠΈΠ°Π»ΡΠ½ΠΎΠΉ Π°ΡΡΠΌΡ (ΠΠ). ΠΡ
Π²ΡΡΠ²ΠΎΠ±ΠΎΠΆΠ΄Π΅Π½ΠΈΠ΅ ΡΠ²ΡΠ·Π°Π½ΠΎ Ρ ΠΈΠΌΠΌΡΠ½ΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠΉ ΠΈ Π½Π΅ΠΈΠΌΠΌΡΠ½ΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠΉ ΡΡΠΈΠΌΡΠ»ΡΡΠΈΠ΅ΠΉ ΡΠ°Π·Π»ΠΈΡΠ½ΡΡ
ΠΊΠ»Π΅ΡΠΎΠΊ, ΠΈΠΌ ΠΎΡΠ²ΠΎΠ΄ΠΈΡΡΡ Π·Π½Π°ΡΠΈΡΠ΅Π»ΡΠ½Π°Ρ ΡΠΎΠ»Ρ Π² ΡΠΎΡΠΌΠΈΡΠΎΠ²Π°Π½ΠΈΠΈ Π²ΠΎΡΠΏΠ°Π»Π΅Π½ΠΈΡ ΠΏΡΠΈ ΠΠ. Lt Π²ΡΠ·ΡΠ²Π°ΡΡ Π±ΡΠΎΠ½Ρ
ΠΎΠΊΠΎΠ½ΡΡΡΠΈΠΊΡΠΈΡ, ΠΏΡΠΈ ΠΊΠΎΡΠΎΡΠΎΠΉ ΡΠ²Π΅Π»ΠΈΡΠΈ-Π²Π°Π΅ΡΡΡ ΡΠΎΡΡΠ΄ΠΈΡΡΠ°Ρ ΠΏΡΠΎΠ½ΠΈΡΠ°Π΅ΠΌΠΎΡΡΡ, ΡΡΠΈΠ»ΠΈΠ²Π°Π΅ΡΡΡ ΠΎΡΠ΅ΠΊ ΡΠ»ΠΈΠ·ΠΈΡΡΠΎΠΉ Π±ΡΠΎΠ½Ρ
ΠΎΠ², ΠΏΠΎΠ²ΡΡΠ°Π΅ΡΡΡ ΡΠ΅ΠΊΡΠ΅ΡΠΈΡ ΡΠ»ΠΈΠ·ΠΈ. ΠΠ·ΡΡΠ΅Π½ΠΈΠ΅ ΠΎΡΠΎΠ±Π΅Π½Π½ΠΎΡΡΠ΅ΠΉ Lt ΠΊΠ°ΠΊ ΠΌΠ΅Π΄ΠΈΠ°ΡΠΎΡΠΎΠ² Π²ΠΎΡΠΏΠ°Π»Π΅Π½ΠΈΡ ΠΏΠΎΠ·Π²ΠΎΠ»ΠΈΠ»ΠΎ ΡΠ°Π·ΡΠ°Π±ΠΎΡΠ°ΡΡ ΠΈ Π²Π½Π΅Π΄ΡΠΈΡΡ Π² ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΡΡ ΠΏΡΠ°ΠΊΡΠΈΠΊΡ Π°Π½ΡΠ°Π³ΠΎΠ½ΠΈΡΡΡ Lt-ΡΠ΅ΡΠ΅ΠΏΡΠΎΡΠΎΠ². ΠΡ
ΠΏΡΠΎΡΠΈΠ²ΠΎΠ²ΠΎΡΠΏΠ°Π»ΠΈΡΠ΅Π»ΡΠ½ΠΎΠ΅ Π΄Π΅ΠΉΡΡΠ²ΠΈΠ΅ ΠΏΠΎΠ·Π²ΠΎΠ»ΡΠ΅Ρ Π΄ΠΎΡΡΠΈΡΡ ΠΊΠΎΠ½ΡΡΠΎΠ»ΠΈΡΡΠ΅ΠΌΠΎΠ³ΠΎ ΡΠ΅ΡΠ΅Π½ΠΈΡ ΠΠ ΠΊΠ°ΠΊ Π² Π²ΠΈΠ΄Π΅ ΠΌΠΎΠ½ΠΎΡΠ΅ΡΠ°ΠΏΠΈΠΈ ΠΏΡΠΈ Π»Π΅Π³ΠΊΠΎΠΌ ΡΠ΅ΡΠ΅Π½ΠΈΠΈ ΠΠ, ΡΠ°ΠΊ ΠΈ Π² ΠΊΠΎΠΌΠ±ΠΈΠ½Π°ΡΠΈΠΈ Ρ Π΄ΡΡΠ³ΠΈΠΌΠΈ ΠΏΡΠΎΡΠΈΠ²ΠΎΠ°ΡΡΠΌΠ°ΡΠΈΡΠ΅ΡΠΊΠΈΠΌΠΈ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠ°ΠΌΠΈ ΠΏΡΠΈ Π±ΠΎΠ»Π΅Π΅ ΡΡΠΆΠ΅Π»ΡΡ
ΡΠΎΡΠΌΠ°Ρ
Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡ. Π Π½Π°ΡΡΠΎΡΡΠ΅Π΅ Π²ΡΠ΅ΠΌΡ Π½Π° ΠΎΡΠ½ΠΎΠ²Π°Π½ΠΈΠΈ ΠΈΠ·ΡΡΠ΅Π½ΠΈΡ ΡΠ΅Π½ΠΎΡΠΈΠΏΠΎΠ² ΠΠ ΠΎΠΏΡΠ΅Π΄Π΅Π»Π΅Π½Ρ ΡΠ΅ ΠΈΠ· Π½ΠΈΡ
, Π² ΠΊΠΎΡΠΎΡΡΡ
ΠΈΠΌΠ΅Π½Π½ΠΎ Lt ΠΈΠΌΠ΅ΡΡ ΠΊΠ»ΡΡΠ΅Π²ΠΎΠ΅ Π·Π½Π°ΡΠ΅Π½ΠΈΠ΅
ΠΠΎΠΌΠ±ΠΈΠ½ΠΈΡΠΎΠ²Π°Π½Π½ΡΠΉ ΠΏΡΠ΅ΠΏΠ°ΡΠ°Ρ βΡΠΈΠΌΠ±ΠΈΠΊΠΎΡΡβ ΠΈ Π΅Π³ΠΎ ΠΌΠ΅ΡΡΠΎ Π² ΡΠ΅ΡΠ°ΠΏΠΈΠΈ Π±ΡΠΎΠ½Ρ ΠΈΠ°Π»ΡΠ½ΠΎΠΉ Π°ΡΡΠΌΡ
.
ΠΠ΅ΡΡΠΎ ΡΠΎΡΠ°Π΄ΠΈΠ»Π° (ΡΠΎΡΠΌΠΎΡΠ΅ΡΠΎΠ»Π° ΡΡΠΌΠ°ΡΠ°ΡΠ°) Π² ΡΠ΅ΡΠ°ΠΏΠΈΠΈ Π±ΡΠΎΠ½Ρ ΠΈΠ°Π»ΡΠ½ΠΎΠΉ Π°ΡΡΠΌΡ ΠΈ Ρ ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΎΠΉ ΠΎΠ±ΡΡΡΡΠΊΡΠΈΠ²Π½ΠΎΠΉ Π±ΠΎΠ»Π΅Π·Π½ΠΈ Π»Π΅Π³ΠΊΠΈΡ
ΠΡΠΎΠ½Ρ ΠΈΠ°Π»ΡΠ½Π°Ρ Π°ΡΡΠΌΠ° ΠΈ Π½Π΅ΡΡΠ΅ΡΠΎΠΈΠ΄Π½ΡΠ΅ ΠΏΡΠΎΡΠΈΠ²ΠΎΠ²ΠΎΡΠΏΠ°Π»ΠΈΡΠ΅Π»ΡΠ½ΡΠ΅ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΡ
ΠΠΎΠ»ΡΡΠΈΠ½ΡΡΠ²ΠΎ Π»ΡΠ΄Π΅ΠΉ Ρ
ΠΎΡΠΎΡΠΎ ΠΏΠ΅ΡΠ΅Π½ΠΎΡΡΡ Π°ΡΠΏΠΈΡΠΈΠ½ ΠΈ Π΄ΡΡΠ³ΠΈΠ΅ Π½Π΅ΡΡΠ΅ΡΠΎΠΈΠ΄Π½ΡΠ΅ ΠΏΡΠΎΡΠΈΠ²ΠΎΠ²ΠΎΡΠΏΠ°Π»ΠΈΡΠ΅Π»ΡΠ½ΡΠ΅ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΡ (ΠΠΠΠ), ΠΎΡΠΎΠ±Π΅Π½Π½ΠΎ, Π΅ΡΠ»ΠΈ ΠΏΡΠΈΠ½ΠΈΠΌΠ°ΡΡ ΠΈΡ
Π² ΡΠ΅ΡΠ΅Π½ΠΈΠ΅ ΠΊΠΎΡΠΎΡΠΊΠΎΠ³ΠΎ Π²ΡΠ΅ΠΌΠ΅Π½ΠΈ. ΠΠ΄Π½Π°ΠΊΠΎ Π½Π΅ΠΊΠΎΡΠΎΡΡΠ΅ ΠΏΠ°ΡΠΈΠ΅Π½ΡΡ ΡΠ²Π»ΡΡΡΡΡ ΠΈΡΠΊΠ»ΡΡΠ΅Π½ΠΈΠ΅ΠΌ ΠΈΠ· ΡΡΠΎΠ³ΠΎ ΠΏΡΠ°Π²ΠΈΠ»Π°. ΠΠΎΠ»ΡΠ½ΡΠ΅ Π±ΡΠΎΠ½Ρ
ΠΈΠ°Π»ΡΠ½ΠΎΠΉ Π°ΡΡΠΌΠΎΠΉ (ΠΠ), ΠΊΠ°ΠΊ ΠΏΡΠ°Π²ΠΈΠ»ΠΎ, ΠΈΡΠΏΠΎΠ»ΡΠ·ΡΡΡ ΠΠΠΠ ΠΏΠΎ ΠΏΠΎΠ²ΠΎΠ΄Ρ ΡΠ°Π·Π»ΠΈΡΠ½ΡΡ
Π½Π΅Π΄ΠΎΠΌΠΎΠ³Π°Π½ΠΈΠΉ, ΠΏΡΠΈ ΡΡΠΎΠΌ Π½Π΅ ΠΎΡΠ΄Π°Π²Π°Ρ ΡΠ΅Π±Π΅ ΠΎΡΡΠ΅ΡΠ° Π² ΠΏΠΎΡΠ΅Π½ΡΠΈΠ°Π»ΡΠ½ΠΎΠΌ ΡΠΈΡΠΊΠ΅ ΡΠ°ΠΊΠΎΠ³ΠΎ Π»Π΅ΡΠ΅Π½ΠΈΡ. Π Π½Π°ΡΡΠΎΡΡΠ΅Π΅ Π²ΡΠ΅ΠΌΡ ΠΏΡΠ°ΠΊΡΠΈΡΠ΅ΡΠΊΠΈ Π²ΠΎ Π²ΡΠ΅Ρ
ΠΈΠ½ΡΡΡΡΠΊΡΠΈΡΡ
ΠΊ ΠΠΠΠ ΡΠΎΠ΄Π΅ΡΠΆΠΈΡΡΡ ΡΠΊΠ°Π·Π°Π½ΠΈΠ΅ Π½Π° Π½Π΅ΠΎΠ±Ρ
ΠΎΠ΄ΠΈΠΌΠΎΡΡΡ ΠΎΡΡΠΎΡΠΎΠΆΠ½ΠΎΠ³ΠΎ ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΡ ΠΈΡ
Ρ Π±ΠΎΠ»ΡΠ½ΡΡ
ΠΠ. Π ΡΡΠΎΠΉ ΡΡΠ°ΡΡΠ΅ ΠΌΡ ΠΏΠΎΡΡΠ°ΡΠ°Π΅ΠΌΡΡ ΠΎΡΠ²Π΅ΡΠΈΡΡ Π½Π° Π²ΠΎΠΏΡΠΎΡ, ΠΏΠΎΡΠ΅ΠΌΡ ΡΡΠ΄ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ ΠΠ Π½Π΅ ΠΌΠΎΠ³ΡΡ ΠΏΡΠΈΠ½ΠΈΠΌΠ°ΡΡ ΠΠΠΠ
ΠΠ»ΠΈΡΠ½ΠΈΠ΅ ΡΠΎΠ±Π»ΡΠ΄Π΅Π½ΠΈΡ Π±Π°Π·ΠΈΡΠ½ΠΎΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ Π½Π° ΡΠ°ΡΡΠΎΡΡ Π³ΠΎΡΠΏΠΈΡΠ°Π»ΠΈΠ·Π°ΡΠΈΠΉ Ρ Π±ΠΎΠ»ΡΠ½ΡΡ Π±ΡΠΎΠ½Ρ ΠΈΠ°Π»ΡΠ½ΠΎΠΉ Π°ΡΡΠΌΠΎΠΉ
The aim of the study was to investigate the influence of compliance to basic therapy for asthma on rate of exacerbations. The asthma patients were interviewed with a specialized questionnaire before and after their studying at asthma-school. The authors revealed that only 12.7 % of the patients were fully compliant with a physician's recommendations on basic therapy and 23.1 % were not before studying; after that the proportion was 69.6 % and 0.7 %, respectively. Before attending the asthma-school, 61.8 % of the patients had 2 or more admissions to a hospital for a year, this number reduced to 4.4 % after school. Therefore, the results highlight a direct relationship between compliance to the basic therapy for asthma and the rate of hospitalizations. This allows significant reduction in hospital admission due to thorough keeping to the physician's recommendations on basic therapy for asthma.Π¦Π΅Π»Ρ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ β ΠΎΡΠ΅Π½ΠΈΡΡ, ΠΊΠ°ΠΊ ΡΠΎΠ±Π»ΡΠ΄Π΅Π½ΠΈΠ΅ Π±Π°Π·ΠΈΡΠ½ΠΎΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ Π²Π»ΠΈΡΠ΅Ρ Π½Π° ΡΠ°ΡΡΠΎΡΡ Π³ΠΎΡΠΏΠΈΡΠ°Π»ΠΈΠ·Π°ΡΠΈΠΉ. ΠΡΠΎΠ²ΠΎΠ΄ΠΈΠ»ΠΎΡΡ Π°Π½ΠΊΠ΅ΡΠΈΡΠΎΠ²Π°Π½ΠΈΠ΅ Π±ΠΎΠ»ΡΠ½ΡΡ
Π±ΡΠΎΠ½Ρ
ΠΈΠ°Π»ΡΠ½ΠΎΠΉ Π°ΡΡΠΌΠΎΠΉ Ρ ΠΏΠΎΠΌΠΎΡΡΡ ΡΠΏΠ΅ΡΠΈΠ°Π»ΠΈΠ·ΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠΉ Π°Π½ΠΊΠ΅ΡΡ-Π²ΠΎΠΏΡΠΎΡΠ½ΠΈΠΊΠ° Π΄ΠΎ ΠΈ ΠΏΠΎΡΠ»Π΅ ΠΎΠ±ΡΡΠ΅Π½ΠΈΡ Π² Π°ΡΡΠΌΠ°-ΡΠΊΠΎΠ»Π΅. ΠΡΡΠ²Π»Π΅Π½ΠΎ, ΡΡΠΎ Π΄ΠΎ ΠΎΠ±ΡΡΠ΅Π½ΠΈΡ Π² Π°ΡΡΠΌΠ°-ΡΠΊΠΎΠ»Π΅ ΠΏΠΎΠ»Π½ΠΎΡΡΡΡ Π²ΡΠΏΠΎΠ»Π½ΡΠ»ΠΈ ΡΠ΅ΠΊΠΎΠΌΠ΅Π½Π΄Π°ΡΠΈΠΈ Π²ΡΠ°ΡΠ° ΠΏΠΎ Π±Π°Π·ΠΈΡΠ½ΠΎΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ Π²ΡΠ΅Π³ΠΎ 12,7 % ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ², Π½Π΅ Π²ΡΠΏΠΎΠ»Π½ΡΠ»ΠΈ 23,1 %, ΠΏΠΎΡΠ»Π΅ ΠΎΠ±ΡΡΠ΅Π½ΠΈΡ β 69,6 ΠΈ 0,7 % ΡΠΎΠΎΡΠ²Π΅ΡΡΡΠ²Π΅Π½Π½ΠΎ. ΠΠΎ ΠΎΠ±ΡΡΠ΅Π½ΠΈΡ 61,8 % Π±ΠΎΠ»ΡΠ½ΡΡ
Π³ΠΎΡΠΏΠΈΡΠ°Π»ΠΈΠ·ΠΈΡΠΎΠ²Π°Π»ΠΈΡΡ 2 ΠΈ Π±ΠΎΠ»Π΅Π΅ ΡΠ°Π· Π² ΡΠ΅ΡΠ΅Π½ΠΈΠ΅ ΠΊΠ°Π»Π΅Π½Π΄Π°ΡΠ½ΠΎΠ³ΠΎ Π³ΠΎΠ΄Π°, ΠΏΠΎΡΠ»Π΅ ΠΎΠ±ΡΡΠ΅Π½ΠΈΡ β 4,4 %. Π’Π°ΠΊΠΈΠΌ ΠΎΠ±ΡΠ°Π·ΠΎΠΌ, ΠΏΠΎΠΊΠ°Π·Π°Π½Π° ΠΏΡΡΠΌΠ°Ρ Π·Π°Π²ΠΈΡΠΈΠΌΠΎΡΡΡ ΠΌΠ΅ΠΆΠ΄Ρ ΡΠΎΠ±Π»ΡΠ΄Π΅Π½ΠΈΠ΅ΠΌ Π±Π°Π·ΠΈΡΠ½ΠΎΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ ΠΈ ΡΠ°ΡΡΠΎΡΠΎΠΉ Π³ΠΎΡΠΏΠΈΡΠ°Π»ΠΈΠ·Π°ΡΠΈΠΉ ΠΈ Π²ΠΎΠ·ΠΌΠΎΠΆΠ½ΠΎΡΡΡ Π·Π½Π°ΡΠΈΡΠ΅Π»ΡΠ½ΠΎΠ³ΠΎ Π΅Π΅ ΡΠ½ΠΈΠΆΠ΅Π½ΠΈΡ Π² ΡΠ»ΡΡΠ°Π΅ Π²ΡΠΏΠΎΠ»Π½Π΅Π½ΠΈΡ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠ°ΠΌΠΈ ΡΠ΅ΠΊΠΎΠΌΠ΅Π½Π΄Π°ΡΠΈΠΉ Π²ΡΠ°ΡΠ° ΠΎΡΠ½ΠΎΡΠΈΡΠ΅Π»ΡΠ½ΠΎ Π±Π°Π·ΠΈΡΠ½ΠΎΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ
ΠΠ΅ΡΠ΅Π½ΠΈΠ΅ Π°Π»Π»Π΅ΡΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ ΡΠΈΠ½ΠΈΡΠΎΠ²: Π²Π½ΠΈΠΌΠ°Π½ΠΈΠ΅ Π½Π° Π±Π΅Π½Π°ΡΠΈΠ½
.
ΠΠΎΠ·ΠΌΠΎΠΆΠ½ΠΎΡΡΠΈ ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΡ ΠΎΡΠ΅ΡΠ΅ΡΡΠ²Π΅Π½Π½ΡΡ Π±ΡΠΎΠ½Ρ ΠΎΠ΄ΠΈΠ»Π°ΡΠ°ΡΠΎΡΠΎΠ² Ρ Π±ΠΎΠ»ΡΠ½ΡΡ Π±ΡΠΎΠ½Ρ ΠΈΠ°Π»ΡΠ½ΠΎΠΉ Π°ΡΡΠΌΠΎΠΉ
Summary. The aim of the study was to evaluate efficacy and safety of Iprafen (Ipratropium bromide + fenoterol) and Ipraspir (Ipratropium bromide). Iprafen was used to relieve symptoms of acute bronchial obstruction (wheezing) in comparison with Berodual H in patients with mildβtoβmoderate persistβent partially controlled asthma. Ipraspir was used as an adjuvant bronchodilator to relieve cough in comparison with Atrovent H in patients with cough and mild persistent partially controlled asthma. Each group allocated for treatment with Iprafen, Berodual H, Ipraspir or Atrovent H involved 30 asthma patients. In all patients, asthma course was stable during the total study period.There were no difference in reduction of cough attacks between patients treated with Berodual H and Iprafen. Additional administration of Atrovent or Ipraspir resulted in nonsignificant reduction in cough frequency and intensity. In both Ipraspir and Atrovent H groups, the need in shortβacting Ξ²2βagonists was decreased. Functional parameters did not differed significantly between Iprafen and Berodual H, Ipraspir and Atrovent H groups. Safety of Iprafen and Ipraspir was similar as of Berodual H and Atrovent H, respectively. Therefore, the study showed equal therapeutic efficacy and safety of the drugs